• GSK J4 HCl: A Chromatin Causality Guide

  2026-08-19

  GSK J4 HCl is a cell-permeable JMJD3 inhibitor for dissecting H3K27 demethylation, inflammatory signaling, and tumor biology. This guide connects product chemistry with a decidual CXCL10 study to show how researchers can design more causal epigenetic assays.

• Annexin V-FITC/7-AAD Apoptosis Kit Guide

  2026-08-19

  The Annexin V-FITC/7-AAD Apoptosis Kit provides a rapid two-parameter readout for distinguishing Annexin V-positive apoptotic phenotypes from 7-AAD-positive membrane-compromised cells. It is appropriate for cell viability, cytotoxicity, and cell death analysis by flow cytometry or fluorescence microscopy, but should not be used alone to establish an apoptotic pathway or to evaluate atypical samples without validation.

• Polyethylenimine Linear: PEI MW 40,000 Workflow

  2026-08-18

  Polyethylenimine Linear (PEI), MW 40,000 supports scalable DNA delivery from 96-well screening to recombinant protein production. This workflow also shows how carefully controlled transfection can extend astrocyte and neuroinflammation studies without confusing a delivery tool with a validated disease mechanism.

• Low-Affinity N-Type Block by v-Agatoxin-IVA

  2026-08-18

  Sidach and Mintz showed that v-Agatoxin-IVA is highly selective for P-type calcium channels at high affinity but can also inhibit a fraction of native N-type currents at higher exposure. Their whole-cell recordings clarify why toxin concentration, membrane potential, and mixed native channel populations must be considered when interpreting P/Q-type pharmacology.

• ARCA EGFP mRNA (5-moUTP) Workflow Guide

  2026-08-17

  Build a reproducible fluorescence-based transfection control with a capped, modified, polyadenylated reporter mRNA. This guide connects practical mRNA transfection in mammalian cells with LNP design, immune-response monitoring, troubleshooting, and assay standardization.

• Carfilzomib (PR-171): Mechanism and Research Workflow

  2026-08-17

  Carfilzomib, also designated PR-171, is an irreversible epoxomicin analog that inhibits proteasome-mediated proteolysis. Its strongest reported activity is against the chymotrypsin-like proteasome function, supporting apoptosis and proteostasis studies in cancer research.

• SR-202: A Translational Lens on PPARγ Biology

  2026-08-16

  SR-202 offers a selective way to interrogate PPARγ-dependent adipogenesis, insulin sensitivity, and immune–metabolic signaling. This thought-leadership perspective connects metabolic models with emerging macrophage-polarization evidence while outlining practical validation and translational boundaries.

• GSK-923295: A Temporal Probe of Mitotic Fidelity

  2026-08-15

  GSK-923295 is a potent CENP-E inhibitor that separates chromosome-motor failure from centromere-architecture defects. This article translates recent CTCF findings into practical assay strategies for cell cycle arrest in mitosis and cancer research.

• GSK126 EZH2 Inhibitor: Experimental Workflows

  2026-08-14

  GSK126 provides a selective, chemically tunable way to suppress EZH2/PRC2 catalytic activity and track H3K27me3-dependent gene silencing. This guide translates the compound into practical workflows for lymphoma, small cell lung cancer, ovarian cancer, and mechanistic studies inspired by lncRNA-mediated EZH2 regulation.

• Ertapenem: From MIC to Gene Mobility

  2026-08-14

  Ertapenem sodium salt can serve as more than a conventional susceptibility reagent. This article presents a mobility-aware research framework that connects phenotypic inhibition, carbapenemase gene location, horizontal transfer, and strain relatedness.

• Aurora A Overexpression in High-Risk Retinoblastoma

  2026-08-13

  A 2024 study identifies Aurora kinase A (AURKA) overexpression as a recurrent feature of human retinoblastoma and links it to histopathologic factors associated with aggressive disease. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, and xenografts, the work supports AURKA as a mechanistically relevant target for retinoblastoma research.

• Imatinib (STI571) as a PDGFR Research Comparator

  2026-08-13

  Imatinib (STI571) can serve as a mechanistic comparator for PDGFR-driven signaling, proliferation, and vascular remodeling studies. This article connects kinase-level measurements with cell and tissue phenotypes while defining how to interpret imatinib alongside more selective PDGFR inhibitors.

• 2,2,2-Trichloroethanol: From Gel Readout to PD Assays

  2026-08-12

  2,2,2-Trichloroethanol is a small molecule biochemical that adds a sensitive protein-level readout to molecular biology research. This article explains how gel-based protein assessment can complement, but not replace, DAT neuroimaging when evaluating dopaminergic cell therapy models.

• Ezh2–p53 Control of Neat1 and Inflammasomes

  2026-08-12

  The reference study identifies a noncanonical, methyltransferase-independent role for Ezh2 in inflammasome activation. Ezh2 preserves H3K27 acetylation at the Neat1 promoter, while p53 recruits SIRT1 to oppose Neat1 transcription, establishing a chromatin-based competition model with implications for interpreting EZH2-targeted experiments.

• Fluconazole: A Benchmark for Resistance Models

  2026-08-11

  Fluconazole is more than a routine antifungal control: it is a mechanistic probe for ergosterol disruption, strain-specific susceptibility, and antifungal drug resistance research. This article translates comparative C. auris evidence into practical assay and model-selection decisions.

15624 records 1/1042 page Next 12345 下5页 Last page